 Immunoglobulin Fab Fragments
"Immunoglobulin Fab Fragments" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
| Descriptor ID |
D007140
|
| MeSH Number(s) |
D12.644.541.500.650 D12.776.124.486.485.680.650 D12.776.124.790.651.680.650 D12.776.377.715.548.680.650
|
| Concept/Terms |
Immunoglobulin Fab Fragments- Immunoglobulin Fab Fragments
- Fab Fragments, Immunoglobulin
- Immunoglobulins, Fab Fragment
- Fab Fragment Immunoglobulins
- Fragment Immunoglobulins, Fab
- Immunoglobulin Fab Fragment
- Fab Fragment, Immunoglobulin
- Fab Immunoglobulin Fragments
- Immunoglobulin Fragments, Fab
- Fab Fragments
- Immunoglobulins, Fab
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Fab Fragments".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Fab Fragments".
This graph shows the total number of publications written about "Immunoglobulin Fab Fragments" by people in this website by year, and whether "Immunoglobulin Fab Fragments" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 2 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 2 | 1 | 3 | | 2001 | 1 | 1 | 2 | | 2002 | 1 | 2 | 3 | | 2003 | 3 | 1 | 4 | | 2004 | 2 | 1 | 3 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 0 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 1 | 1 | 2 | | 2015 | 1 | 2 | 3 | | 2016 | 0 | 1 | 1 | | 2017 | 2 | 0 | 2 | | 2018 | 3 | 0 | 3 | | 2019 | 4 | 0 | 4 | | 2020 | 1 | 0 | 1 | | 2022 | 0 | 1 | 1 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunoglobulin Fab Fragments" by people in Profiles.
-
Borowska MT, Boughter CT, Bunker JJ, Guthmiller JJ, Wilson PC, Roux B, Bendelac A, Adams EJ. Biochemical and biophysical characterization of natural polyreactivity in antibodies. Cell Rep. 2023 10 31; 42(10):113190.
-
Trautman WJ, Ahmed F, Barton DJ, Abesamis MG, Lynch MJ. Safe administration of Crotalidae equine immune F(ab')2 antivenom in a patient who suffered anaphylaxis from Crotalidae polyvalent immune Fab antivenom. Am J Emerg Med. 2023 10; 72:221.e1-221.e3.
-
Brandehoff N, Dalton A, Daugherty C, Dart RC, Monte AA. Total CroFab and Anavip Antivenom Vial Administration in US Rattlesnake Envenomations: 2019-2021. J Med Toxicol. 2023 07; 19(3):248-254.
-
Spyres MB, Padilla GK, Gerkin RD, Hoyte CO, Wolk BJ, Ruha AM. Late hemotoxicity following North American rattlesnake envenomation treated with crotalidae immune F(ab')2 (equine) antivenom and crotalidae immune polyvalent Fab (ovine) antivenom reported to the North American Snakebite Sub-registry. Clin Toxicol (Phila). 2022 07; 60(7):838-842.
-
Martin AM, Wang GS, Poel K. Use of both Fab and F(ab')2 fragment antivenom in a pediatric patient for treatment of a North American Crotalidae envenomation. Am J Emerg Med. 2021 07; 45:677.e1-677.e3.
-
Lavonas EJ, Burnham RI, Schwarz J, Quackenbush E, Lewis B, Rose SR, Greene S, Toschlog EA, Charlton NP, Mullins ME, Schwartz R, Denning D, Sharma K, Kleinschmidt K, Bush SP, Anderson VE, Ginde AA, Gerardo CJ. Recovery from Copperhead Snake Envenomation: Role of Age, Sex, Bite Location, Severity, and Treatment. J Med Toxicol. 2020 01; 16(1):17-23.
-
Palmer KG, Lebin JA, Cronin MT, Mazor SS, Burns RA. Crataegus mexicana (Tejocote) Exposure Associated with Cardiotoxicity and a Falsely Elevated Digoxin Level. J Med Toxicol. 2019 Oct; 15(4):295-298.
-
Dart RC, Bush SP, Heard K, Arnold TC, Sutter M, Campagne D, Holstege CP, Seifert SA, Lo JCY, Quan D, Borron S, Meurer DA, Burnham RI, McNally J, Garcia-Ubbelohde W, Anderson VE. The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Ann Emerg Med. 2019 09; 74(3):439-449.
-
Gerardo CJ, Vissoci JRN, de Oliveira LP, Anderson VE, Quackenbush E, Lewis B, Rose SR, Greene S, Toschlog EA, Charlton NP, Mullins ME, Schwartz R, Denning D, Sharma K, Kleinschmidt K, Bush SP, Brandehoff NP, Lavonas EJ. The validity, reliability and minimal clinically important difference of the patient specific functional scale in snake envenomation. PLoS One. 2019; 14(3):e0213077.
-
Mullins ME, Gerardo CJ, Bush SP, Rose SR, Greene S, Quackenbush EB, Lewis B, Anderson VE, Kleinschmidt KC, Schwarz RB, Charlton NP, Toschlog EA, Sharma K, Denning DA, Lavonas EJ. Adverse Events in the Efficacy of Crotalidae Polyvalent Immune Fab Antivenom vs Placebo in Recovery from Copperhead Snakebite Trial. South Med J. 2018 12; 111(12):716-720.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|